A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes
- 16 February 2007
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 153 (3) , 445.e1-445.e6
- https://doi.org/10.1016/j.ahj.2006.11.005
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- C-Reactive Protein Levels and Outcomes after Statin TherapyNew England Journal of Medicine, 2005
- Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- Evidence for a Potent Antiinflammatory Effect of RosiglitazoneJournal of Clinical Endocrinology & Metabolism, 2004
- C-Reactive Protein and Incident Cardiovascular Events Among Men With DiabetesDiabetes Care, 2004
- Marked low‐density lipoprotein cholesterol reduction below current national cholesterol education program targets provides the greatest reduction in carotid atherosclerosisClinical Cardiology, 2004
- Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitusAtherosclerosis, 2003
- ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing CholesterolCirculation, 2002
- Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.Circulation, 2002
- Differential Effects of Metformin and Troglitazone on Cardiovascular Risk Factors in Patients With Type 2 DiabetesDiabetes Care, 2002
- Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ, 2000